newsfilter
← Latest News
Business Wire·

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Study evaluating BRUKINSA® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting